Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a sulfonyl moiety as potent dual inhibitors of PLK1 and BRD4

Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a hydrazone moiety as potent PLK1 inhibitors

(2020) Zhiwei Li et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of Methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a Potent and Selective Polo-like Kinase 1 (PLK1) Inhibitor for Combating Hepatocellular Carcinoma

(2020) Zhou Deng et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants

(2020) Minglin Zhu et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes

(2020) Jingjing Chen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity

(2019) Ellen Watts et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dual or multi-targeting inhibitors: The next generation anticancer agents

(2018) Nulgumnalli Manjunathaiah Raghavendra et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors

(2018) Shuai Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and biological evaluation of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivative as potent antitumor agents

(2018) Yunlei Hou et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

PLK1, A Potential Target for Cancer Therapy

(2017) Zhixian Liu et al.   Translational Oncology

Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells

(2016) Yuma Nonomiya et al.   CANCER SCIENCE

Application of Sulfonyl in Drug Design

(2016) Fei Zhao et al.   CHINESE JOURNAL OF ORGANIC CHEMISTRY

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

(2016) Brian K. Albrecht et al.   JOURNAL OF MEDICINAL CHEMISTRY

BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments

(2015) Rodrigo F.E. Bogado et al.   ANTI-CANCER DRUGS

Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors

(2014) Stuart W. J. Ember et al.   ACS Chemical Biology

Polypharmacology: Challenges and Opportunities in Drug Discovery

(2014) Andrew Anighoro et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

(2014) Pietro Ciceri et al.   Nature Chemical Biology

Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-b]pyran-7-ones Designed as Next Generation PI3K Inhibitors

(2013) Guillermo A. Morales et al.   JOURNAL OF MEDICINAL CHEMISTRY

Polypharmacology – Foe or Friend?

(2013) Jens-Uwe Peters   JOURNAL OF MEDICINAL CHEMISTRY

Bioorthogonal Probes for Polo-like Kinase 1 Imaging and Quantification

(2011) Ghyslain Budin et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage

(2008) S. Giordano et al.   CURRENT MEDICINAL CHEMISTRY